These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 8501169)

  • 1. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome.
    Kamp GA; Kuilboer MM; Wynne HJ; Rongen-Westerlaken C; Johnson ML; Veldhuis JD; Wit JM
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1604-9. PubMed ID: 8501169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
    Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased metabolic clearance of endogenous growth hormone and specific alterations in the pulsatile mode of growth hormone secretion occur in prepubertal girls with Turner's syndrome. Genentech Collaborative Group.
    Veldhuis JD; Sotos JF; Sherman BM
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1073-80. PubMed ID: 1939522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
    Nilsson KO; Albertsson-Wikland K; Alm J; Aronson S; Gustafsson J; Hagenäs L; Häger A; Ivarsson SA; Karlberg J; Kriström B; Marcus C; Moell C; Ritzen M; Tuvemo T; Wattsgård C; Westgren U; Westphal O; Aman J
    J Clin Endocrinol Metab; 1996 Feb; 81(2):635-40. PubMed ID: 8636281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation.
    Hokken-Koelega AC; Hackeng WH; Stijnen T; Wit JM; de Muinck Keizer-Schrama SM; Drop SL
    J Clin Endocrinol Metab; 1990 Sep; 71(3):688-95. PubMed ID: 2394775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol.
    Massa G; Bouillon R; Vanderschueren-Lodeweyckx M
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1298-302. PubMed ID: 1430092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone treatment in Turner's syndrome: short and long-term effects on metabolic parameters.
    Haeusler G; Frisch H
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):247-53. PubMed ID: 1563078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific, time-dependent actions of low-dose ethinyl estradiol administration on the episodic release of growth hormone, follicle-stimulating hormone, and luteinizing hormone in prepubertal girls with Turner's syndrome.
    Mauras N; Rogol AD; Veldhuis JD
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1053-8. PubMed ID: 2507569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Mouton JW; Blum WF; Mercado M; Baumann G; Drop SL
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
    Saggese G; Federico G; Cinquanta L
    Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of acute high dose and chronic low dose estrogen on plasma somatomedin-C and growth in patients with Turner's syndrome.
    Copeland KC
    J Clin Endocrinol Metab; 1988 Jun; 66(6):1278-82. PubMed ID: 3372687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone.
    Bergmann P; Valsamis J; Van Perborgh J; De Schepper J; Van Vliet G
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1461-7. PubMed ID: 2229302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
    Haeusler G; Schmitt K; Blümel P; Plöchl E; Waldhör T; Frisch H
    J Clin Endocrinol Metab; 1996 Feb; 81(2):536-41. PubMed ID: 8636264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome.
    Massa G; Maes M; Heinrichs C; Vandeweghe M; Craen M; Vanderschueren-Lodeweyckx M
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):253-60. PubMed ID: 8458097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related perception of stature, acceptance of therapy, and psychosocial functioning in human growth hormone-treated girls with Turner's syndrome.
    Lagrou K; Xhrouet-Heinrichs D; Heinrichs C; Craen M; Chanoine JP; Malvaux P; Bourguignon JP
    J Clin Endocrinol Metab; 1998 May; 83(5):1494-501. PubMed ID: 9589645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose turnover and insulin clearance after growth hormone treatment in girls with Turner's syndrome.
    Monti LD; Brambilla P; Caumo A; Magni F; Omati S; Nizzoli G; di Natale B; Galli-Kienle M; Cobelli C; Chiumello G; Pozza G
    Metabolism; 1997 Dec; 46(12):1482-8. PubMed ID: 9439548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth factor I.
    Foster CM; Borondy M; Markovs ME; Hopwood NJ; Kletter GB; Beitins IZ
    Pediatr Res; 1994 Feb; 35(2):218-22. PubMed ID: 7513079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of four computerized models to estimate 24-hour growth hormone secretion in girls with Turner's syndrome.
    Kuilboer MM; Kleijer B; Kamp GA; Veldhuis JD; Johnson ML; Wit JM
    Horm Res; 1992; 38(3-4):125-33. PubMed ID: 1306843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.
    Vanderschueren-Lodeweyckx M; Massa G; Maes M; Craen M; van Vliet G; Heinrichs C; Malvaux P
    J Clin Endocrinol Metab; 1990 Jan; 70(1):122-6. PubMed ID: 2294126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone therapy in Turner's syndrome: an update on final height. Genentech National Cooperative Study Group.
    Rosenfeld RG
    Acta Paediatr Suppl; 1992 Sep; 383():3-6; discussion 7. PubMed ID: 1458013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.